振东制药(300158) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥762,822,569.10, a decrease of 10.35% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2024 was ¥9,465,852.30, an increase of 161.40% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥368,936.29, up 101.81% from the previous year[3] - Total operating revenue for Q3 2024 was ¥2,269,424,815.15, a decrease of 18.4% compared to ¥2,783,745,444.64 in Q3 2023[19] - Net profit for Q3 2024 was ¥36,565,014.67, a significant recovery from a net loss of ¥4,134,073.59 in the same period last year[20] - The company reported a basic earnings per share of ¥0.0392, compared to a loss per share of ¥0.0009 in Q3 2023[20] - The company's basic earnings per share for Q3 2024 was ¥0.0094, an increase of 162.67% compared to the same period last year[3] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥110,772,794.15, an improvement of 50.38% compared to the same period last year[9] - Cash flow from operating activities showed a net outflow of ¥110,772,794.15, an improvement from a net outflow of ¥223,264,687.72 in the previous year[22] - The net increase in cash and cash equivalents was -¥420,247,299.54, a significant decline compared to an increase of ¥254,437,509.60 in the previous period[23] - The ending balance of cash and cash equivalents dropped to ¥342,571,365.19 from ¥938,160,243.88, indicating a liquidity challenge[23] - Cash inflow from financing activities totaled ¥70,375,939.12, compared to ¥69,429,550.44 in the previous period, reflecting a slight increase[23] - Cash outflow from financing activities decreased to ¥205,982,949.46 from ¥225,241,729.12 year-over-year, indicating improved cash management[23] - Net cash flow from financing activities improved to -¥135,607,010.34 from -¥155,812,178.68, showing a reduction in cash outflow[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,881,625,188.66, a decrease of 4.84% from the end of the previous year[3] - The total number of common shareholders at the end of the reporting period is 53,306[10] - The total assets decreased from CNY 6,180,497,035.31 at the beginning of the period to CNY 5,881,625,188.66 at the end of the period, representing a decline of approximately 4.85%[17] - Current assets decreased from CNY 4,460,291,739.61 to CNY 3,952,475,367.21, a reduction of about 11.4%[17] - Total liabilities decreased from CNY 1,036,388,580.76 to CNY 801,652,020.83, a reduction of approximately 22.7%[18] - The company's equity attributable to shareholders decreased from CNY 5,178,856,723.52 to CNY 5,116,529,308.97, a decline of about 1.2%[18] - The non-current liabilities decreased from CNY 119,314,194.81 to CNY 69,797,039.00, a reduction of approximately 41.5%[18] Shareholder Information - Shanxi Zhendong Health Industry Group Co., Ltd. holds 30.06% of shares, totaling 302,230,191 shares, with 226,314,986 shares pledged[10] - The top ten shareholders account for 38.74% of the total share capital[12] - The company repurchased and canceled 22,174,904 shares on July 15, 2024, reducing the total share capital from 1,027,494,660 shares to 1,005,319,756 shares[15] - The number of restricted shares held by Li Anping increased to 2,316,272 shares, with 579,068 shares added during the period[14] - The total number of shares held by the top ten shareholders participating in margin trading is 4,060,800 shares[11] - The percentage of shares held by the top ten shareholders at the beginning of the period was 29.34%[12] Other Financial Metrics - The weighted average return on equity was 0.19%, a slight decrease from the previous year[3] - The investment income from financial products increased to ¥34,278,947.85, a rise of 44.42% year-on-year[8] - Research and development expenses increased to ¥146,074,950.49 from ¥137,283,367.79, indicating a focus on innovation[19] - Sales expenses decreased to ¥837,111,655.22 from ¥1,072,756,701.01, reflecting cost control measures[19] - The company achieved an operating profit of ¥57,057,425.50, compared to an operating profit of ¥11,737,348.50 in the previous year[19] - Other comprehensive income after tax was ¥304,241.41, a recovery from a loss of ¥31,342,821.29 in Q3 2023[20] Regulatory and Compliance - The company has received an arbitration notice regarding a contract dispute with Beijing Landi Pharmaceutical Co., Ltd.[15] - The company has not disclosed any related party relationships among the top shareholders[11] - The company has not reported any changes in the number of preferred shareholders or restricted shares during the period[13] - The company has not yet adopted the new accounting standards for the current fiscal year, which may impact future financial reporting[23] - The third quarter report has not been audited, which may affect the reliability of the financial data presented[23]